TP53 and ovarian cancer: TR100 (stage IIA, adenocarcinoma, 61-year-old male with occupation risk) has a TP53 non-sense mutation c.892G>T characterized as pathogenic with high impact on protein function and reported in rhabdomyosarcoma, neoplasm of ovary, hereditary cancer-predisposing syndrome, and Li–Fraumeni syndrome.